Congress 2014 has ended
Friday, May 2 • 10:15am - 11:45am
Updates in Melanoma: Immune-Modulating Agents and Molecular-Targeted Therapies

Sign up or log in to save this to your schedule and see who's attending!

Stay current on investigational and U.S. Food and Drug Administration-approved immune and molecular-targeted therapies, from common side effects to treatment algorithms. You’ll explore anti-CTLA4 antibodies, anti-PD1 antibodies, and BRAF and MEK inhibitors. Other key topics include CKIT-, NRAS-, and CMET-targeted therapies.

1. Identify current immune-modulating therapies and immune-related adverse events.
2. Plan treatment algorithms for immune-related adverse events.
3. Evaluate the ability to use molecular-targeted therapies for melanoma treatment based on identified somatic mutations.

This session qualifies for the following ONCC Individual Learning Needs Assessment (ILNA) categories.

OCN®: Scientific Basis for Practice, Treatment Modalities
AOCNP®: Diagnosis, Staging, and Treatment Planning, Cancer Treatment
AOCNS®: Diagnosis, Staging, and Treatment Planning, Cancer Treatment


avatar for Brianna Hoffner, MSN, RN, ANP-BC, AOCNP®

Brianna Hoffner, MSN, RN, ANP-BC, AOCNP®

The Angeles Clinic and Research Institute
Full disclosure: Nothing to disclose.

Matthew Burke, MBA, RN, MSN, APRN-BC

Yale-New Haven Hospital
Full disclosure: Nothing to disclose.

Friday May 2, 2014 10:15am - 11:45am
Ballroom E Anaheim Convention Center, 800 W. Katella Avenue. Anaheim, CA 92802

Attendees (0)